NewcelX Ltd. Launches Following Merger Completion
The merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. has successfully concluded, resulting in the rebranding of the combined entity as NewcelX Ltd. This newly formed company is set to trade on the Nasdaq Capital Market under the ticker symbol "NCEL." This merger represents a significant shift in the biotechnology landscape, bringing together pioneering discoveries in cell therapy and drug development.
Key Details of the Merger Announcement
NewcelX Ltd. has transitioned from the former NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and has completed the merger agreement that was initially established on November 4, 2024. Effective as of October 30, 2025, the merger has positioned NewcelX for dynamic growth and innovation in the biopharmaceutical industry as it embarks on a new chapter.
Exchange Ratio and Share Structure
In accordance with the merger agreement, shareholders of Kadimastem received a notable exchange rate of 0.706 shares of NewcelX for each ordinary share owned prior to the merger. This exchange was notably adjusted for a reverse stock split ratio of 1-for-10 instituted by NewcelX, aligning with the merger's execution.
Enhancing Value for Shareholders
Holders of common and preferred shares, as well as warrants from NLS at the time of the merger, have also received contingent value rights tied to future success from some of NewcelX's legacy assets. This strategic approach aims at maximizing shareholder value through future revenue streams, including potential proceeds from clinical developments.
Leadership Insights on the Merger
The completion of this merger has been underscored by comments from the executives. Prof. Michel Revel, Chief Scientific Officer of NewcelX, highlighted the capabilities of the new organization, emphasizing its commitment to harnessing cell therapy and innovative drug discovery to improve patient outcomes, particularly for those battling amyotrophic lateral sclerosis (ALS), diabetes, and other neurodegenerative diseases.
Strategic Focus and Clinical Development Plans
As the newly branded NewcelX, preparations are underway to initiate a Phase 2a clinical trial of AstroRx™ aimed at ALS, alongside advancements in the development of IsletRx™ for Type 1 diabetes treatment. This direction underscores NewcelX's commitment to groundbreaking therapies that could alter the quality of life for individuals with chronic conditions.
Company Leadership and Governance Structure
NewcelX is strategically headquartered in Zurich, Switzerland, under the leadership of Ronen Twito, serving as Executive Chairman and Chief Executive Officer. His team includes renowned scientists and experts from both NLS Pharmaceutics and Kadimastem, including a mix of visionary leaders in biotechnology.
About NewcelX Ltd.
NewcelX Ltd. (NASDAQ: NCEL) operates with an integrated biotechnology platform focusing on developing transformative therapies for neurodegenerative and metabolic diseases. By combining advanced stem cell technology and neuroscience, the company aims to launch scalable and effective treatments specifically targeting conditions such as ALS and Type 1 diabetes.
Frequently Asked Questions
What is NewcelX Ltd.?
NewcelX Ltd. is a biotechnology company formed through the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., focusing on innovative therapies for neurodegenerative diseases.
What are the ticker symbols for NewcelX Ltd.?
The company will trade under the ticker symbol "NCEL" on the Nasdaq Capital Market.
What therapies is NewcelX developing?
NewcelX is actively developing treatments for conditions like ALS and Type 1 diabetes, leveraging cutting-edge cell-based therapies and drug discovery.
Who is leading NewcelX Ltd.?
Ronen Twito serves as the Executive Chairman and CEO, leading a team of experts in biotechnology and regenerative medicine.
What can shareholders expect post-merger?
Shareholders can expect potential future value from the new company structure, improved clinical outcomes, and innovative therapy pipelines aimed at chronic illnesses.
